Background: Intravenous immunoglobulins (IVIGs) are scarce biological products used in a broad variety of disorders. Tolerance to infusions is usually good but adverse events, including some serious ones, have been reported.Aim of the work: The study aimed for detection of adverse events that occur during and following intravenous immunoglobulin (IVIG) infusion; in relation to preparation, dosing regimen, duration and infusion hours, with identification of patients at risk of developing these adverse events.Patients and methods: To detect the complications of IVIG infusions, an observational study was implemented on a cohort of 55 patients (birth to18 years) who received 62 infusion sessions for different disease conditions over a period of 6 months, 2013. Clinical evaluation and laboratory assessment were done with follow up 7-10 days afterwards. Results: Adverse events occurred following 37.1% of IVIG infusions ranging from common mild rate related reactions such as skin rash, fever and chills to more severe anaphylactoid ones as serum sickness (3.2%) and rare ones such as significant anemia (22.6%) and acute renal failure (3.2%). Infusion rate and the presence of risk factors are strong predicting variable for numerous reactions. Conclusions: Proper rationale and usage with close monitoring of administration setting, dosage and infusion rate can avoid some of these reactions. Weighing benefits and hazards is essential in patients with risk factors.